
Hana Å torkÃ;novÃ;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5466619/publications.pdf Version: 2024-02-01



ΗΛΝΛ ΔΤΟΡΚΑ:ΝΟΛΑ:

#	Article	IF	CITATIONS
1	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	3.3	9,439
2	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	1.9	17
3	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research and Therapy, 2021, 23, 173.	3.5	8
4	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. Rheumatology, 2021, 60, 5060-5072.	1.9	6
5	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	3.2	5
6	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. Frontiers in Medicine, 2022, 9, .	2.6	5
7	Female Sexual Dysfunction and Pelvic Floor Muscle Function Associated with Systemic Sclerosis: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 612.	2.6	3
8	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study. Frontiers in Immunology, 2022, 13, 811045.	4.8	2
9	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.8	1
10	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clinical and Experimental Rheumatology, 2021, 39, 1021-1032.	0.8	1
11	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. Clinical and Experimental Rheumatology, 0, , .	0.8	1
12	08.48â€Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
13	08.49â€Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients – preliminary data from a single-centre controlled study. , 2017, , .		0
14	08.47â€Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
15	AB0687â€EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES – PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
16	OP0066â€EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WIT SYSTEMIC SCLEROSIS – PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .	Н	0
17	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up Clinical and Experimental Rheumatology, 2022, , .	0.8	0